Fertility
Fertility start-up bags US$10.3m investment to launch ‘innovative’ membership model
Through the new model, Oova says it aims to address women’s health needs holistically

The US women’s health and fertility start-up Oova has secured US$10.3m in funding to support women trying to conceive.
The company, which developed an at-home urine test that measures both luteinising hormone and progesterone to detect the most fertile days and confirm ovulation, is now expanding its at-home approach through a new subscription model.
The Oova membership would include The Oova Kit and would offer features such as personalised support and access to an online community.
“We recognise that women seeking to start or expand their families desire more than just a test or a tool—they want a comprehensive solution,” said Oova founder and CEO, Amy Divaraniya.
“With the introduction of the Oova membership, we are excited to provide women with a plan for the next steps in their journey to parenthood.
“By combining expert guidance, personalised recommendations, and a supportive community, we aim to empower women and ensure they have the tools they need to make informed decisions about their reproductive health.”
An expert in biomedical sciences, Divaraniya launched Oova after her personal struggles to conceive emphasised the lack of resources women have to access information about their own bodies.
Through the new membership model, led by funding from Spero Ventures, the founder says she aims to address women’s health needs holistically.
“Oova has really revolutionised the way we understand our hormonal health,” said Sara Eshelman, partner at Spero Ventures.
“By making clinical-grade hormone monitoring convenient and cost-effective for daily use, Oova is empowering its users to understand their cycles, improve fertility outcomes, and manage their symptoms.
“Simultaneously, Oova offers intricate datasets that provide patients and clinicians an unprecedented objective understanding of how hormones affect our health and well-being.
“We are honored to be part of the team’s mission to bring these capabilities to women, and to clinical care as a whole.”
Dr Eduardo Hariton, managing director of US Fertility Innovation Fund, said: “The US Fertility Innovation Fund is proud to partner with and invest in companies with the potential to transform the reproductive space.
“Oova is poised to do so by providing a more convenient and cost-effective way to measure reproductive hormones at home.
“Their assays have been rigorously validated and provide accurate results in minutes, allowing them to meet the unique needs of both patients and providers without some of the hurdles of venipuncture.”
Fertility
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Mental health
Housing, work and fertility stop Britons having the families they want – research
Menopause7 days agoPerimenopause misinformation ‘putting women at risk’
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Mental health4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’














Pingback: US women’s health start-up launches at-home perimenopause hormone kit - FemTech World